Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Andrew X. Zhu, Richard S. Finn, Yoon‐Koo Kang, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Guido Gerken, John Bilbruck, Yanzhi Hsu, Kun Liang, Ryan C. Widau, Chunxiao Wang, Paolo Abada, Masatoshi Kudo (2021). Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British Journal of Cancer, 124(8), pp. 1388-1397, DOI: 10.1038/s41416-021-01260-w.
Article353 days agoEffect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo, Peter R. Galle, Giovanni Brandi, Yoon‐Koo Kang, Chia-Jui Yen, Richard S. Finn, Josep M. Llovet, Éric Assenat, Philippe Merle, Stephen L. Chan, Daniel H. Palmer, Masafumi Ikeda, Tatsuya Yamashita, Arndt Vogel, Yi‐Hsiang Huang, Paolo Abada, Reigetsu Yoshikawa, Kenta Shinozaki, Chunxiao Wang, Ryan C. Widau, Andrew X. Zhu (2020). Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Reports, 3(2), pp. 100215-100215, DOI: 10.1016/j.jhepr.2020.100215.
Article353 days agoPrognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)
Andrew X. Zhu, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Yoon‐Koo Kang, Chung‐Jen Yen, Éric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Tim Meyer, Ryan C. Widau, William R. Schelman, C. Wang, Yanzhi Hsu, Masatoshi Kudo (2019). Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2). Annals of Oncology, 30, pp. v289-v290, DOI: 10.1093/annonc/mdz247.079.
Article353 days agoRamucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites.
Andrew X. Zhu, Masafumi Ikeda, Peter R. Galle, Tatsuya Yamashita, Josep M. Llovet, Kun Liang, Chunxiao Wang, Sachi Sakaguchi, Paolo Abada, Ryan C. Widau, Masatoshi Kudo (2020). Ramucirumab in patients with advanced HCC and elevated alpha-fetoprotein (AFP): Outcomes by treatment-emergent ascites.. Journal of Clinical Oncology, 38(15_suppl), pp. 4644-4644, DOI: 10.1200/jco.2020.38.15_suppl.4644.
Article353 days agoMulticenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD
Masafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, Masatoshi Kudo, Yoshitaka Inaba, Manabu Morimoto, Kaoru Tsuchiya, Satoshi Shimizu, Yasushi Kojima, Atsushi Hiraoka, Kazuhiro Nouso, Hiroshi Aikata, Kazushi Numata, Tosiya Sato, Takuji Okusaka, Junji Furuse (2023). Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD. , 13(2), DOI: https://doi.org/10.1159/000531820.
Article15 days ago